Literature DB >> 759068

Noninvasive kinetic approach to the estimation of total hepatic blood flow and shunting in chronic liver disease--a hypothesis.

A McLean, P du Souich, M Gibaldi.   

Abstract

The intact hepatocyte theory of chronic liver disease suggests a relationship between the degree of shunting of total liver blood flow around the functional liver cell mass and the fraction of functional liver cell mass. By defining this relationship we have developed pharmacokinetic equations to permit the estimation of both total hepatic blood flow and the extent to which this blood flow is shunted. The method requires the determination of the systemic (hepatic) clearances of a high (e.g., indocyanine green [ICG]) and a low (e.g., antipyrine [AP]) extraction ratio drug in the same patient. Applying these equations to literature data obtained from patients with moderate or severe chronic liver disease and from patients with a surgical portacaval shunt, we find: (1) a modest decrease in total hepatic blood flow (16%) and a significant degree of shunting (27%) in patients with moderate chronic liver disease; (2) a substantially reduced total hepatic blood (52%) and extensive shunting (72%) in patients with severe chronic liver disease, and (3) a degree of shunting comparable to that estimated in patients with moderate chronic liver disease but a seriously compromised total hepatic blood flow (a reduction of 55% compared to normal) in patients with surgical portacaval shunts.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 759068     DOI: 10.1002/cpt1979252161

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Clinical significance of pharmacokinetic models of hepatic elimination.

Authors:  D J Morgan; R A Smallwood
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

2.  Per rectal thallium scintigraphy for the assessment of portosystemic shunt: an experimental study in the bile duct ligated rats.

Authors:  L Van Maldergem; O Jeghers; G Cadiere; C de Prez; H R Ham; A Piepsz
Journal:  Eur J Nucl Med       Date:  1989

3.  Pharmacokinetics of biliary excretion in man V. Dibromosulfophthalein.

Authors:  D K Meijer; J G Weitering; G A Vermeer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Clinical pharmacokinetics of hydralazine.

Authors:  T M Ludden; J L McNay; A M Shepherd; M S Lin
Journal:  Clin Pharmacokinet       Date:  1982 May-Jun       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

6.  The clinical value of 201Tl per rectum scintigraphy in the work-up of patients with alcoholic liver disease.

Authors:  D Urbain; P Reding; B Georges; O Thys; H R Ham
Journal:  Eur J Nucl Med       Date:  1986

Review 7.  Influence of food intake on presystemic clearance of drugs.

Authors:  A Melander; A McLean
Journal:  Clin Pharmacokinet       Date:  1983 Jul-Aug       Impact factor: 6.447

8.  A semiphysiological population pharmacokinetic model of agomelatine and its metabolites in Chinese healthy volunteers.

Authors:  Feifan Xie; An Vermeulen; Pieter Colin; Zeneng Cheng
Journal:  Br J Clin Pharmacol       Date:  2019-03-21       Impact factor: 4.335

9.  Blood ammonia levels in liver cirrhosis: a clue for the presence of portosystemic collateral veins.

Authors:  Giovanni Tarantino; Vincenzo Citro; Pasquale Esposito; Sabrina Giaquinto; Annalisa de Leone; Graziella Milan; Francesca Saveria Tripodi; Michele Cirillo; Roberto Lobello
Journal:  BMC Gastroenterol       Date:  2009-03-17       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.